Abstract
There is mounting evidence both from experimental and clinical studies that traumatic brain injury (TBI) is associated with a reduction of aerobic metabolism. This results from a variable combination of impaired substrate delivery and mitochondrial failure. Mitochondria, which are responsible for the production of 95% of cell adenosine triphosphate (ATP), may become compromised after TBI. On the other hand, in the very early period after the primary injury, oxygen delivery may be impaired due to arterial hypoxia and/or to a reduction of cerebral blood flow (CBF). As a consequence, 80-90% of patients who die of head injury show ischemia on histo-pathological examination of the brain tissue. In the absence of an appropriate treatment for TBI, these observations favored the hypothesis that manipulation of brain oxygen delivery could be a therapeutic tool to improve aerobic metabolism. Several strategies were developed, including the increase of cerebral perfusion pressure (CPP) using amines or the increase of arterial partial pressure of oxygen (PaO2) through hyperbaric oxygen (HBO) or normobaric hyperoxia. Several experimental and clinical studies, using normobaric hyperoxia, demonstrated an increase in brain tissue oxygen tension and a reduction of brain extracellular lactate levels, but there is no consensus about the biological meaning of these findings. For some authors, they translate an improvement of brain oxidative metabolism, while for others they represent only biological epiphenomena. The current review addresses the rational behind normobaric hyperoxia as a therapeutic application and discusses the experimental and clinical results achieved so far.
Keywords: normobaric hyperoxia, traumatic brain injury, aerobic metabolism, brain hypoxia
Current Pharmaceutical Design
Title: Arterial Hyperoxia in Severe Head Injury: A Useful or Harmful Option?
Volume: 10 Issue: 18
Author(s): O. L. Alves, W. P. Daugherty and M. Rios
Affiliation:
Keywords: normobaric hyperoxia, traumatic brain injury, aerobic metabolism, brain hypoxia
Abstract: There is mounting evidence both from experimental and clinical studies that traumatic brain injury (TBI) is associated with a reduction of aerobic metabolism. This results from a variable combination of impaired substrate delivery and mitochondrial failure. Mitochondria, which are responsible for the production of 95% of cell adenosine triphosphate (ATP), may become compromised after TBI. On the other hand, in the very early period after the primary injury, oxygen delivery may be impaired due to arterial hypoxia and/or to a reduction of cerebral blood flow (CBF). As a consequence, 80-90% of patients who die of head injury show ischemia on histo-pathological examination of the brain tissue. In the absence of an appropriate treatment for TBI, these observations favored the hypothesis that manipulation of brain oxygen delivery could be a therapeutic tool to improve aerobic metabolism. Several strategies were developed, including the increase of cerebral perfusion pressure (CPP) using amines or the increase of arterial partial pressure of oxygen (PaO2) through hyperbaric oxygen (HBO) or normobaric hyperoxia. Several experimental and clinical studies, using normobaric hyperoxia, demonstrated an increase in brain tissue oxygen tension and a reduction of brain extracellular lactate levels, but there is no consensus about the biological meaning of these findings. For some authors, they translate an improvement of brain oxidative metabolism, while for others they represent only biological epiphenomena. The current review addresses the rational behind normobaric hyperoxia as a therapeutic application and discusses the experimental and clinical results achieved so far.
Export Options
About this article
Cite this article as:
Alves L. O., Daugherty P. W. and Rios M., Arterial Hyperoxia in Severe Head Injury: A Useful or Harmful Option?, Current Pharmaceutical Design 2004; 10 (18) . https://dx.doi.org/10.2174/1381612043384187
DOI https://dx.doi.org/10.2174/1381612043384187 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Food-derived bioactive peptides against chronic diseases
Chronic diseases, such as cardiovascular diseases and metabolic diseases, have become a great threat to the human health in recent decades due to the excessive food consumption and the prevalence of sedentary lifestyle. As a class of natural compounds, food-derived bioactive peptides have been demonstrated to possess great potential for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cell Therapy for Ischaemic Stroke: Translation from Preclinical Studies to Clinical Treatment
CNS & Neurological Disorders - Drug Targets Positive Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 2 (mGluR2)
Current Topics in Medicinal Chemistry Genetic and Molecular Approaches to the Immunopathogenesis of Multiple Sclerosis: An Update
Current Molecular Medicine Tauopathies – Focus on Changes at the Neurovascular Unit
Current Alzheimer Research Special Issue on Stem Cells: An Introduction from the Guest Editor
Current Neurovascular Research Quantitative Ultrasound in Diagnosis of Metabolic Bone Diseases
Current Medical Imaging A Non-Steroidal Anti-Inflammatory Agent Provides Significant Protection During Focal Ischemic Stroke with Decreased Expression of Matrix Metalloproteinases
Current Neurovascular Research The Potential Impact of Sirtuin 1 Protein on Premature Ovarian Insufficiency
Current Proteomics Structure-Activity Relationships and Therapeutic Potential of Purinergic P2X7 Receptor Antagonists
Current Medicinal Chemistry Unraveling Progesterone-Induced Molecular Mechanisms in Physiological and Pathological Conditions
Current Clinical Pharmacology Retinoic Acid Induced 1, RAI1: A Dosage Sensitive Gene Related to Neurobehavioral Alterations Including Autistic Behavior
Current Genomics Cholinergic Drugs as Therapeutic Tools in Inflammatory Diseases: Participation of Neuronal and Non-Neuronal Cholinergic Systems.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Chlorogenic Acid: A Dietary Phenolic Acid with Promising Pharmacotherapeutic Potential
Current Medicinal Chemistry Urocortins: Putative Role in Cardiovascular Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Discovery and Development of Non-Dopaminergic Agents for the Treatment of Schizophrenia: Overview of the Preclinical and Early Clinical Studies
Current Medicinal Chemistry The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders I: Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Recent Patents on Cardiovascular Stem Cells
Recent Patents on Cardiovascular Drug Discovery Impact of Cellular Senescence in Aging and Cancer
Current Pharmaceutical Design Clozapine Safety, 35 Years Later
Current Drug Safety Targeting Cancer Stem Cell Lines as a New Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery